Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of VX-121/Tezacaftor/Deutivacaftor in Moderate Hepatic Impairment
NCT05437120Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vanzacaftor and deutivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at Day 23, Area Under the Concentration Versus Time Curve at Day 23 and 3 more. Started Jul 2022; status: completed.
02
Drugs
vanzacaftordeutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05437120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05437120.